Incidence of HOX11, HOX11L2, SIL-TAL1, and CALM-AF10 within pediatric, adolescent, and adult T-ALLs, classified by immunophenotype
. | . | TCR- T-ALLs . | . | TCR+ T-ALLs . | . | ||
|---|---|---|---|---|---|---|---|
. | Total . | IM0/δ/γ . | IMβ and pre-αβ . | TCRαβ . | TCRγδ . | ||
| Children | 40 | 3 (8) | 16 (40) | 12 (30) | 9 (22) | ||
| Mean age, y (range)* | 6.3 (0.3-10) | 9.7 (9-10) | 5.7 (2-9) | 6.2 (0.3-10) | 6.2 (1-10) | ||
| SIL-TAL1, no (%) | 9 (23) | (0) | 4 (25) | 5 (42) | (0) | ||
| HOX11, no (%) | 1 (3) | (0) | 1 (6) | (0) | (0) | ||
| HOX11L2, no (%) | 9 (23) | (0) | 8 (50) | (0) | 1 (11) | ||
| CALM-AF10, no (%) | 2 (5) | (0) | (0) | (0) | 2 (22) | ||
| MG-, no (%) | 19 (48) | 3 (100) | 3 (19) | 7 (58) | 6 (67) | ||
| Adolescents | 45 | 10 (22) | 21 (46) | 9 (20) | 5 (11) | ||
| Mean age, y (range)† | 15.5 (11-20) | 15.0 (12-20) | 16.1 (12-20) | 15.2 (11-20) | 14.4 (11-20) | ||
| SIL-TAL1, no (%) | 7 (16) | (0) | 4 (19) | 3 (33) | (0) | ||
| HOX11, no (%) | 4 (9) | (0) | 4 (19) | (0) | (0) | ||
| HOX11L2, no (%) | 7 (16) | (0) | 4 (19) | (0) | 3 (60) | ||
| CALM-AF10, no (%) | 6 (13) | 4 (40) | (0) | (0) | 2 (40) | ||
| MG-, no (%) | 21 (47) | 6 (60) | 9 (43) | 6 (67) | (0) | ||
| Adults | 80 | 30 (38) | 33 (41) | 7 (9) | 10 (12) | ||
| Mean age, y (range)‡ | 33.9 (21-78) | 32.9 (21-78) | 34.0 (22-66) | 37.3 (24-53) | 31.2 (26-40) | ||
| SIL-TAL1, no (%) | 4 (5) | (0) | 2 (6) | 2 (29) | (0) | ||
| HOX11, no (%) | 14 (18) | 1 (3) | 12 (36) | (0) | 1 (10) | ||
| HOX11L2, no (%) | 9 (11) | (0) | 6 (18) | 2 (29) | 1 (10) | ||
| CALM-AF10, no (%) | 10 (13) | 8 (27) | (0) | (0) | 2 (20) | ||
| MG-, no (%) | 43 (54) | 21 (70) | 13 (39) | 3 (42) | 6 (60) | ||
. | . | TCR- T-ALLs . | . | TCR+ T-ALLs . | . | ||
|---|---|---|---|---|---|---|---|
. | Total . | IM0/δ/γ . | IMβ and pre-αβ . | TCRαβ . | TCRγδ . | ||
| Children | 40 | 3 (8) | 16 (40) | 12 (30) | 9 (22) | ||
| Mean age, y (range)* | 6.3 (0.3-10) | 9.7 (9-10) | 5.7 (2-9) | 6.2 (0.3-10) | 6.2 (1-10) | ||
| SIL-TAL1, no (%) | 9 (23) | (0) | 4 (25) | 5 (42) | (0) | ||
| HOX11, no (%) | 1 (3) | (0) | 1 (6) | (0) | (0) | ||
| HOX11L2, no (%) | 9 (23) | (0) | 8 (50) | (0) | 1 (11) | ||
| CALM-AF10, no (%) | 2 (5) | (0) | (0) | (0) | 2 (22) | ||
| MG-, no (%) | 19 (48) | 3 (100) | 3 (19) | 7 (58) | 6 (67) | ||
| Adolescents | 45 | 10 (22) | 21 (46) | 9 (20) | 5 (11) | ||
| Mean age, y (range)† | 15.5 (11-20) | 15.0 (12-20) | 16.1 (12-20) | 15.2 (11-20) | 14.4 (11-20) | ||
| SIL-TAL1, no (%) | 7 (16) | (0) | 4 (19) | 3 (33) | (0) | ||
| HOX11, no (%) | 4 (9) | (0) | 4 (19) | (0) | (0) | ||
| HOX11L2, no (%) | 7 (16) | (0) | 4 (19) | (0) | 3 (60) | ||
| CALM-AF10, no (%) | 6 (13) | 4 (40) | (0) | (0) | 2 (40) | ||
| MG-, no (%) | 21 (47) | 6 (60) | 9 (43) | 6 (67) | (0) | ||
| Adults | 80 | 30 (38) | 33 (41) | 7 (9) | 10 (12) | ||
| Mean age, y (range)‡ | 33.9 (21-78) | 32.9 (21-78) | 34.0 (22-66) | 37.3 (24-53) | 31.2 (26-40) | ||
| SIL-TAL1, no (%) | 4 (5) | (0) | 2 (6) | 2 (29) | (0) | ||
| HOX11, no (%) | 14 (18) | 1 (3) | 12 (36) | (0) | 1 (10) | ||
| HOX11L2, no (%) | 9 (11) | (0) | 6 (18) | 2 (29) | 1 (10) | ||
| CALM-AF10, no (%) | 10 (13) | 8 (27) | (0) | (0) | 2 (20) | ||
| MG-, no (%) | 43 (54) | 21 (70) | 13 (39) | 3 (42) | 6 (60) | ||
MG- T-ALLs are negative by molecular genetics (MG) for HOX11, HOX11L2, SIL-TAL1, and CALM-AF10.
Mean ages for children were as follows: SIL-TAL1, 5.1 years (3-9 years); HOX11, 4.0 years; HOX11L2, 6.3 years (5-8 years); CALM-AF10, 4.5 years (3-6 years); and MG-, 6.8 years (0.3-10 years)
Mean ages for adolescents were as follows: SIL-TAL1, 15.9 years (11-20 years); HOX11, 15.5 years (12-20 years); HOX11L2, 13.9 years (11-17 years); CALM-AF10, 13.8 years (11-20 years); and MG-, 16.3 years (12-20 years)
Mean ages for adolescents were as follows: SIL-TAL1, 29.5 years (22-40 years); HOX11, 40.4 years (24-66 years); HOX11L2, 28.1 years (22-37 years); CALM-AF10, 28.1 years (23-43 years); and MG-, 36.4 years (21-78 years)